SlideShare ist ein Scribd-Unternehmen logo
1 von 4
Val in Crs
MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% CORPORATE MAT MTH
76567 100.00 5.9 6636 100.00 8.1 IPM
1 1 4893 6.39 3.8 414 6.44 4.8 Abbott + Abbott HC + Novo `1 1
2 2 4168 5.44 15.4 377 5.34 15.2 Sun Pharma 2 2
3 3 3809 4.97 6.2 326 4.97 6.8 Cipla `2 3
4 4 3363 4.39 6.3 281 4.39 4.3 Zydus + Biochem 3 4
5 6 2836 3.70 -3.6 233 3.98 -4.7 Ranbaxy `3 7
6 5 2727 3.56 5.4 243 3.50 13.3 Mankind `5 9
7 8 2710 3.54 -15.6 227 4.02 -7.8 Glaxo 4 6
8 9 2673 3.49 9.9 226 3.39 8.3 Alkem + Cachet + Indchemie 5 8
9 7 2581 3.37 11.7 230 3.36 11.7 Lupin `4 5
10 11 2226 2.91 3.0 189 2.95 4.0 Pfizer 6 11
11 12 2162 2.82 15.0 183 2.65 12.9 Emcure + Zuventus `6 12
12 10 2056 2.69 11.5 198 2.55 26.7 Macleods 7 10
13 13 1926 2.52 0.3 175 2.65 7.7 Sanofi `7 13
14 14 1909 2.49 7.0 168 2.55 7.4 Intas 8 14
15 15 1877 2.45 14.7 164 2.17 23.1 Aristo `8 15
16 18 1667 2.18 15.7 131 1.89 13.6 Glenmark 9 18
17 16 1635 2.14 5.7 144 2.16 8.9 Dr. Reddys `9 16
18 17 1572 2.05 9.3 139 2.15 5.7 Micro + Bal 10 17
19 21 1407 1.84 9.1 118 1.87 3.1 USV `10 21
20 19 1394 1.82 14.0 127 1.79 15.1 Torrent 11 19
21 20 1372 1.79 20.4 124 1.59 27.8 IPCA `11 20
22 22 1222 1.60 3.0 102 1.53 8.6 Wockhardt 12 22
23 23 1133 1.48 -1.3 94 1.55 -1.4 Novartis `12 23
24 24 1056 1.38 10.5 86 1.23 13.4 Alembic 13 24
25 25 812 1.06 2.3 72 1.13 2.8 FDC `13 25
26 27 793 1.04 8.2 70 0.98 16.1 Unichem 14 27
27 26 784 1.02 7.7 70 0.95 19.6 MSD + Fulford + Organon `14 26
28 28 616 0.80 11.4 55 0.83 7.7 Cadila 15 28
29 29 592 0.77 5.3 50 0.72 13.2 Indoco Remedies 16 30
30 31 567 0.74 11.6 48 0.69 13.5 Franco `16 31
31 30 566 0.74 24.1 50 0.72 13.4 Eris `15 29
32 32 470 0.61 3.0 44 0.63 14.1 Himalaya 17 32
33 34 465 0.61 8.9 42 0.60 13.9 Merck `17 34
34 43 429 0.56 -41.4 30 0.97 -49.8 Elder 18 42
35 37 423 0.55 1.5 35 0.50 14.2 Blue Cross `19 37
36 33 405 0.53 11.0 43 0.65 6.8 JB Chemicals 19 33
37 40 395 0.52 16.7 32 0.51 0.9 Astrazeneca `18 39
38 39 383 0.50 -10.7 32 0.65 -19.7 Bharat Serums 20 40
39 36 376 0.49 -1.0 35 0.54 5.5 Raptakos, Brett `20 35
40 35 372 0.49 21.0 35 0.45 27.5 Meyer Organics 21 36
41 38 361 0.47 7.8 33 0.46 16.8 Wallace + Indi Pharma `21 38
42 45 347 0.45 11.6 28 0.39 17.0 Hetero `23 51
With Bonus Units at Full Value Witho
Rank MAT May-14 May-14 Rank
43 42 333 0.43 7.6 30 0.44 10.4 Medley 23 43
44 44 330 0.43 0.6 29 0.45 3.3 Win-Medicare 22 44
45 41 318 0.41 33.4 31 0.33 54.1 Akumentis 24 41
46 48 317 0.41 10.8 27 0.41 8.1 Janssen `22 46
47 47 311 0.41 3.3 27 0.44 2.1 Albert David `24 47
48 50 293 0.38 47.9 26 0.30 44.8 Biocon 25 49
49 46 284 0.37 33.4 28 0.31 45.0 Ajanta `25 45
50 52 277 0.36 25.2 26 0.37 14.3 Hegde & Hegde 26 50
Val (Cr) MS% GR% Val (Cr) MS% GR%
73629 100.00 5.9 6397 100.00 8.7
4794 6.51 3.5 407 6.36 5.2
4073 5.53 14.4 370 5.78 15.2
3572 4.85 9.0 307 4.80 10.3
3143 4.27 6.1 264 4.12 5.7
2743 3.73 -3.6 225 3.52 -4.7
2306 3.13 6.9 208 3.25 16.9
2675 3.63 -14.9 226 3.53 -6.2
2483 3.37 9.7 212 3.31 10.0
2524 3.43 11.6 226 3.53 12.1
2176 2.95 3.3 185 2.89 4.6
2097 2.85 15.3 178 2.78 13.5
1927 2.62 11.2 186 2.90 26.8
1890 2.57 0.0 172 2.68 7.6
1884 2.56 6.4 166 2.60 7.7
1654 2.25 11.9 143 2.23 20.5
1619 2.20 15.3 128 2.00 13.4
1602 2.18 4.9 141 2.21 8.8
1503 2.04 9.9 134 2.09 6.3
1401 1.90 9.0 118 1.84 3.4
1370 1.86 13.8 124 1.94 14.5
1305 1.77 20.0 120 1.87 29.4
1197 1.63 2.7 100 1.56 8.7
1092 1.48 -0.6 91 1.42 0.4
1023 1.39 11.0 83 1.30 14.3
790 1.07 2.2 69 1.08 3.2
776 1.05 7.5 68 1.06 16.1
774 1.05 7.6 69 1.07 18.8
594 0.81 11.2 53 0.83 7.6
551 0.75 5.6 47 0.73 13.4
546 0.74 11.0 46 0.72 13.3
563 0.76 23.9 50 0.77 13.3
468 0.64 2.6 44 0.68 13.8
454 0.62 7.5 41 0.64 12.6
413 0.56 -39.8 29 0.46 -47.7
389 0.53 3.5 32 0.50 13.5
389 0.53 10.8 41 0.64 6.1
391 0.53 15.8 31 0.49 0.5
375 0.51 -11.2 31 0.49 -19.9
371 0.50 -1.3 35 0.54 5.6
360 0.49 20.8 34 0.53 27.5
331 0.45 11.7 32 0.50 28.5
315 0.43 11.9 25 0.40 17.9
Without Bonus Units
MAT May -14 May-14
316 0.43 8.3 29 0.45 10.3
325 0.44 -0.6 28 0.44 1.7
311 0.42 35.4 31 0.48 54.7
317 0.43 10.7 27 0.43 8.1
305 0.41 3.2 27 0.42 1.9
292 0.40 47.9 26 0.41 44.7
282 0.38 33.3 27 0.43 44.9
276 0.38 25.2 26 0.40 14.3

Weitere ähnliche Inhalte

Was ist angesagt?

Digital 2023 Turks and Caicos Islands (February 2023) v01
Digital 2023 Turks and Caicos Islands (February 2023) v01Digital 2023 Turks and Caicos Islands (February 2023) v01
Digital 2023 Turks and Caicos Islands (February 2023) v01DataReportal
 
Digital 2023 Argentina (February 2023) v01
Digital 2023 Argentina (February 2023) v01Digital 2023 Argentina (February 2023) v01
Digital 2023 Argentina (February 2023) v01DataReportal
 
Digital 2023 Zambia (February 2023) v01
Digital 2023 Zambia (February 2023) v01Digital 2023 Zambia (February 2023) v01
Digital 2023 Zambia (February 2023) v01DataReportal
 
Digital 2023 Lebanon (February 2023) v01
Digital 2023 Lebanon (February 2023) v01Digital 2023 Lebanon (February 2023) v01
Digital 2023 Lebanon (February 2023) v01DataReportal
 
Digital 2023 Norway (February 2023) v01
Digital 2023 Norway (February 2023) v01Digital 2023 Norway (February 2023) v01
Digital 2023 Norway (February 2023) v01DataReportal
 
Digital 2023 Netherlands (February 2023) v01
Digital 2023 Netherlands (February 2023) v01Digital 2023 Netherlands (February 2023) v01
Digital 2023 Netherlands (February 2023) v01DataReportal
 
Digital 2023 South Korea (February 2023) v01
Digital 2023 South Korea (February 2023) v01Digital 2023 South Korea (February 2023) v01
Digital 2023 South Korea (February 2023) v01DataReportal
 
Digital 2023 Japan (February 2023) v01
Digital 2023 Japan (February 2023) v01Digital 2023 Japan (February 2023) v01
Digital 2023 Japan (February 2023) v01DataReportal
 
Digital 2023 Oman (February 2023) v01
Digital 2023 Oman (February 2023) v01Digital 2023 Oman (February 2023) v01
Digital 2023 Oman (February 2023) v01DataReportal
 
Rheumatoid arthritis management
Rheumatoid arthritis management Rheumatoid arthritis management
Rheumatoid arthritis management Praveen Nagula
 
Glycolic acid peel for acne: is it still relevant?
Glycolic acid peel for acne: is it still relevant?Glycolic acid peel for acne: is it still relevant?
Glycolic acid peel for acne: is it still relevant?peternugraha
 
Digital 2023 Guyana (February 2023) v01
Digital 2023 Guyana (February 2023) v01Digital 2023 Guyana (February 2023) v01
Digital 2023 Guyana (February 2023) v01DataReportal
 
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스Taejoon Yoo
 
Digital 2023 United States Virgin Islands (February 2023) v01
Digital 2023 United States Virgin Islands (February 2023) v01Digital 2023 United States Virgin Islands (February 2023) v01
Digital 2023 United States Virgin Islands (February 2023) v01DataReportal
 
Digital 2023 Jordan (February 2023) v01
Digital 2023 Jordan (February 2023) v01Digital 2023 Jordan (February 2023) v01
Digital 2023 Jordan (February 2023) v01DataReportal
 
Digital 2023 Qatar (February 2023) v01
Digital 2023 Qatar (February 2023) v01Digital 2023 Qatar (February 2023) v01
Digital 2023 Qatar (February 2023) v01DataReportal
 
Digital 2023 Hong Kong (February 2023) v01
Digital 2023 Hong Kong (February 2023) v01Digital 2023 Hong Kong (February 2023) v01
Digital 2023 Hong Kong (February 2023) v01DataReportal
 
PRODUCT LIST OF ALIVE PHARMACEUTICAL
PRODUCT LIST OF ALIVE PHARMACEUTICAL PRODUCT LIST OF ALIVE PHARMACEUTICAL
PRODUCT LIST OF ALIVE PHARMACEUTICAL Santosh Adhikari
 

Was ist angesagt? (20)

Digital 2023 Turks and Caicos Islands (February 2023) v01
Digital 2023 Turks and Caicos Islands (February 2023) v01Digital 2023 Turks and Caicos Islands (February 2023) v01
Digital 2023 Turks and Caicos Islands (February 2023) v01
 
Digital 2023 Argentina (February 2023) v01
Digital 2023 Argentina (February 2023) v01Digital 2023 Argentina (February 2023) v01
Digital 2023 Argentina (February 2023) v01
 
Digital 2023 Zambia (February 2023) v01
Digital 2023 Zambia (February 2023) v01Digital 2023 Zambia (February 2023) v01
Digital 2023 Zambia (February 2023) v01
 
Digital 2023 Lebanon (February 2023) v01
Digital 2023 Lebanon (February 2023) v01Digital 2023 Lebanon (February 2023) v01
Digital 2023 Lebanon (February 2023) v01
 
Digital 2023 Norway (February 2023) v01
Digital 2023 Norway (February 2023) v01Digital 2023 Norway (February 2023) v01
Digital 2023 Norway (February 2023) v01
 
Digital 2023 Netherlands (February 2023) v01
Digital 2023 Netherlands (February 2023) v01Digital 2023 Netherlands (February 2023) v01
Digital 2023 Netherlands (February 2023) v01
 
Digital 2023 South Korea (February 2023) v01
Digital 2023 South Korea (February 2023) v01Digital 2023 South Korea (February 2023) v01
Digital 2023 South Korea (February 2023) v01
 
Digital 2023 Japan (February 2023) v01
Digital 2023 Japan (February 2023) v01Digital 2023 Japan (February 2023) v01
Digital 2023 Japan (February 2023) v01
 
Digital 2023 Oman (February 2023) v01
Digital 2023 Oman (February 2023) v01Digital 2023 Oman (February 2023) v01
Digital 2023 Oman (February 2023) v01
 
Rheumatoid arthritis management
Rheumatoid arthritis management Rheumatoid arthritis management
Rheumatoid arthritis management
 
Glycolic acid peel for acne: is it still relevant?
Glycolic acid peel for acne: is it still relevant?Glycolic acid peel for acne: is it still relevant?
Glycolic acid peel for acne: is it still relevant?
 
Digital 2023 Guyana (February 2023) v01
Digital 2023 Guyana (February 2023) v01Digital 2023 Guyana (February 2023) v01
Digital 2023 Guyana (February 2023) v01
 
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스
MindsLab seminar(20140527) 03_실시간 마켓센싱을 위한 마켓인텔리젼스
 
Digital 2023 United States Virgin Islands (February 2023) v01
Digital 2023 United States Virgin Islands (February 2023) v01Digital 2023 United States Virgin Islands (February 2023) v01
Digital 2023 United States Virgin Islands (February 2023) v01
 
Gaps in Medical Science Liaison Training
Gaps in Medical Science Liaison TrainingGaps in Medical Science Liaison Training
Gaps in Medical Science Liaison Training
 
Digital 2023 Jordan (February 2023) v01
Digital 2023 Jordan (February 2023) v01Digital 2023 Jordan (February 2023) v01
Digital 2023 Jordan (February 2023) v01
 
Digital 2023 Qatar (February 2023) v01
Digital 2023 Qatar (February 2023) v01Digital 2023 Qatar (February 2023) v01
Digital 2023 Qatar (February 2023) v01
 
Digital 2023 Hong Kong (February 2023) v01
Digital 2023 Hong Kong (February 2023) v01Digital 2023 Hong Kong (February 2023) v01
Digital 2023 Hong Kong (February 2023) v01
 
PRODUCT LIST OF ALIVE PHARMACEUTICAL
PRODUCT LIST OF ALIVE PHARMACEUTICAL PRODUCT LIST OF ALIVE PHARMACEUTICAL
PRODUCT LIST OF ALIVE PHARMACEUTICAL
 
Pathology of Arthritis
Pathology of ArthritisPathology of Arthritis
Pathology of Arthritis
 

Mehr von Anup Soans

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...Anup Soans
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardAnup Soans
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingAnup Soans
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thAnup Soans
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMAnup Soans
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021Anup Soans
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsAnup Soans
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentAnup Soans
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramAnup Soans
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramAnup Soans
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsAnup Soans
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow Anup Soans
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectAnup Soans
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramAnup Soans
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsAnup Soans
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollAnup Soans
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceAnup Soans
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 IssueAnup Soans
 

Mehr von Anup Soans (20)

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way Forward
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and Spending
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAM
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand Patients
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop Talent
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification Program
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification Program
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research Project
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification Program
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian Doctors
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View Poll
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient Experience
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 Issue
 

Indian Pharma Top 50 Companies - May 2014

  • 1. Val in Crs MAT MTH Val (Cr) MS% GR% Val (Cr) MS% GR% CORPORATE MAT MTH 76567 100.00 5.9 6636 100.00 8.1 IPM 1 1 4893 6.39 3.8 414 6.44 4.8 Abbott + Abbott HC + Novo `1 1 2 2 4168 5.44 15.4 377 5.34 15.2 Sun Pharma 2 2 3 3 3809 4.97 6.2 326 4.97 6.8 Cipla `2 3 4 4 3363 4.39 6.3 281 4.39 4.3 Zydus + Biochem 3 4 5 6 2836 3.70 -3.6 233 3.98 -4.7 Ranbaxy `3 7 6 5 2727 3.56 5.4 243 3.50 13.3 Mankind `5 9 7 8 2710 3.54 -15.6 227 4.02 -7.8 Glaxo 4 6 8 9 2673 3.49 9.9 226 3.39 8.3 Alkem + Cachet + Indchemie 5 8 9 7 2581 3.37 11.7 230 3.36 11.7 Lupin `4 5 10 11 2226 2.91 3.0 189 2.95 4.0 Pfizer 6 11 11 12 2162 2.82 15.0 183 2.65 12.9 Emcure + Zuventus `6 12 12 10 2056 2.69 11.5 198 2.55 26.7 Macleods 7 10 13 13 1926 2.52 0.3 175 2.65 7.7 Sanofi `7 13 14 14 1909 2.49 7.0 168 2.55 7.4 Intas 8 14 15 15 1877 2.45 14.7 164 2.17 23.1 Aristo `8 15 16 18 1667 2.18 15.7 131 1.89 13.6 Glenmark 9 18 17 16 1635 2.14 5.7 144 2.16 8.9 Dr. Reddys `9 16 18 17 1572 2.05 9.3 139 2.15 5.7 Micro + Bal 10 17 19 21 1407 1.84 9.1 118 1.87 3.1 USV `10 21 20 19 1394 1.82 14.0 127 1.79 15.1 Torrent 11 19 21 20 1372 1.79 20.4 124 1.59 27.8 IPCA `11 20 22 22 1222 1.60 3.0 102 1.53 8.6 Wockhardt 12 22 23 23 1133 1.48 -1.3 94 1.55 -1.4 Novartis `12 23 24 24 1056 1.38 10.5 86 1.23 13.4 Alembic 13 24 25 25 812 1.06 2.3 72 1.13 2.8 FDC `13 25 26 27 793 1.04 8.2 70 0.98 16.1 Unichem 14 27 27 26 784 1.02 7.7 70 0.95 19.6 MSD + Fulford + Organon `14 26 28 28 616 0.80 11.4 55 0.83 7.7 Cadila 15 28 29 29 592 0.77 5.3 50 0.72 13.2 Indoco Remedies 16 30 30 31 567 0.74 11.6 48 0.69 13.5 Franco `16 31 31 30 566 0.74 24.1 50 0.72 13.4 Eris `15 29 32 32 470 0.61 3.0 44 0.63 14.1 Himalaya 17 32 33 34 465 0.61 8.9 42 0.60 13.9 Merck `17 34 34 43 429 0.56 -41.4 30 0.97 -49.8 Elder 18 42 35 37 423 0.55 1.5 35 0.50 14.2 Blue Cross `19 37 36 33 405 0.53 11.0 43 0.65 6.8 JB Chemicals 19 33 37 40 395 0.52 16.7 32 0.51 0.9 Astrazeneca `18 39 38 39 383 0.50 -10.7 32 0.65 -19.7 Bharat Serums 20 40 39 36 376 0.49 -1.0 35 0.54 5.5 Raptakos, Brett `20 35 40 35 372 0.49 21.0 35 0.45 27.5 Meyer Organics 21 36 41 38 361 0.47 7.8 33 0.46 16.8 Wallace + Indi Pharma `21 38 42 45 347 0.45 11.6 28 0.39 17.0 Hetero `23 51 With Bonus Units at Full Value Witho Rank MAT May-14 May-14 Rank
  • 2. 43 42 333 0.43 7.6 30 0.44 10.4 Medley 23 43 44 44 330 0.43 0.6 29 0.45 3.3 Win-Medicare 22 44 45 41 318 0.41 33.4 31 0.33 54.1 Akumentis 24 41 46 48 317 0.41 10.8 27 0.41 8.1 Janssen `22 46 47 47 311 0.41 3.3 27 0.44 2.1 Albert David `24 47 48 50 293 0.38 47.9 26 0.30 44.8 Biocon 25 49 49 46 284 0.37 33.4 28 0.31 45.0 Ajanta `25 45 50 52 277 0.36 25.2 26 0.37 14.3 Hegde & Hegde 26 50
  • 3. Val (Cr) MS% GR% Val (Cr) MS% GR% 73629 100.00 5.9 6397 100.00 8.7 4794 6.51 3.5 407 6.36 5.2 4073 5.53 14.4 370 5.78 15.2 3572 4.85 9.0 307 4.80 10.3 3143 4.27 6.1 264 4.12 5.7 2743 3.73 -3.6 225 3.52 -4.7 2306 3.13 6.9 208 3.25 16.9 2675 3.63 -14.9 226 3.53 -6.2 2483 3.37 9.7 212 3.31 10.0 2524 3.43 11.6 226 3.53 12.1 2176 2.95 3.3 185 2.89 4.6 2097 2.85 15.3 178 2.78 13.5 1927 2.62 11.2 186 2.90 26.8 1890 2.57 0.0 172 2.68 7.6 1884 2.56 6.4 166 2.60 7.7 1654 2.25 11.9 143 2.23 20.5 1619 2.20 15.3 128 2.00 13.4 1602 2.18 4.9 141 2.21 8.8 1503 2.04 9.9 134 2.09 6.3 1401 1.90 9.0 118 1.84 3.4 1370 1.86 13.8 124 1.94 14.5 1305 1.77 20.0 120 1.87 29.4 1197 1.63 2.7 100 1.56 8.7 1092 1.48 -0.6 91 1.42 0.4 1023 1.39 11.0 83 1.30 14.3 790 1.07 2.2 69 1.08 3.2 776 1.05 7.5 68 1.06 16.1 774 1.05 7.6 69 1.07 18.8 594 0.81 11.2 53 0.83 7.6 551 0.75 5.6 47 0.73 13.4 546 0.74 11.0 46 0.72 13.3 563 0.76 23.9 50 0.77 13.3 468 0.64 2.6 44 0.68 13.8 454 0.62 7.5 41 0.64 12.6 413 0.56 -39.8 29 0.46 -47.7 389 0.53 3.5 32 0.50 13.5 389 0.53 10.8 41 0.64 6.1 391 0.53 15.8 31 0.49 0.5 375 0.51 -11.2 31 0.49 -19.9 371 0.50 -1.3 35 0.54 5.6 360 0.49 20.8 34 0.53 27.5 331 0.45 11.7 32 0.50 28.5 315 0.43 11.9 25 0.40 17.9 Without Bonus Units MAT May -14 May-14
  • 4. 316 0.43 8.3 29 0.45 10.3 325 0.44 -0.6 28 0.44 1.7 311 0.42 35.4 31 0.48 54.7 317 0.43 10.7 27 0.43 8.1 305 0.41 3.2 27 0.42 1.9 292 0.40 47.9 26 0.41 44.7 282 0.38 33.3 27 0.43 44.9 276 0.38 25.2 26 0.40 14.3